07/22/22 8:00 AMNasdaq : IMAB clinical trialI-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1BB Bispecific Antibody TJ-CD4B in Solid Tumors in ChinaI-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the first patient in China has been treated withRHEA-AIneutral
07/18/22 8:00 AMNasdaq : IMAB conferencesclinical trialI-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that an abstract reporting the latest clinical data fromRHEA-AIneutral
07/06/22 8:00 AMNasdaq : IMAB conferencesI-Mab to Host 2022 R&D DayI-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it will host its 2022 Research andRHEA-AIneutral
06/23/22 8:00 AMNasdaq : IMAB I-Mab Receives Top Rankings in Five Categories by Institutional InvestorI-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it was ranked among the top companies inRHEA-AIvery positive
06/15/22 10:37 AMNasdaq : IMAB, MOR I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced two assets the Company has licensed from partnerRHEA-AIvery positive
06/15/22 8:41 AMNasdaq : IMAB, MOR I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced two assets the Company has licensed from partnerRHEA-AIvery positive
06/14/22 4:01 PMNasdaq : MOR, IMAB MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210...RHEA-AIvery positive
06/14/22 5:19 AMNasdaq : IMAB clinical trialGenexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)Genexine a publicly traded, clinical stage biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, today announced that its partner, I-Mab, recently completed patient enrollment in a phase 3 clinical trial of its proprietary long-acting growth hormone, eftansomatropin alfa, also...RHEA-AIneutral
06/09/22 7:00 AMNasdaq : IMAB Ferring Announces New Collaboration for Development of OlamkiceptFerring Pharmaceuticals today announced it has entered into a strategic collaboration with I-Mab to further develop olamkicept in inflammatory bowel disease and related inflammatory conditions. Ferring had previously entered into a license agreement with I-Mab in 2016 that granted I-Mab exclusive rights to develop and...RHEA-AIvery positive
06/07/22 12:49 AMNasdaq : IMAB clinical trialGenexine reports encouraging top-line results of the Phase 1b/2 clinical trial with GX-I7 (efineptakin alfa) in refractory or recurrent (R/R) metastatic Triple Negative Breast CancerGenexine a publicly traded, clinical stage biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, today announced top-line results from the KEYNOTE-899 phase 1 b/2 clinical trial of GX-I7 in combination with pembrolizumab. Genexine presented these data in a poster presentation...RHEA-AIneutral